Your session is about to expire
← Back to Search
Fludarabine for Sickle Cell Disease
Study Summary
This trial is testing a new drug to see if it can help people with sickle cell disease before they have a blood stem cell transplant. The goal is to see if the drug can reduce the patient's cells from rejecting donor cells after the transplant.
- Sickle Cell Disease
- Sickle Cell Anemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are being taken into this clinical investigation?
"Yes, records from clinicaltrials.gov indicate that this trial is actively seeking volunteers. It was first published on October 19th 2015 and most recently updated on May 27th 2022, with the aim of enrolling 25 participants at 1 centre."
Are there other researches conducted using Fludarabine?
"Presently, 369 clinical trials are ongoing related to Fludarabine with 22 of them in the advanced stages. Most studies occur in Boston, MA but there are 3,764 medical centres running experiments for this drug around the world."
What criteria must be met for someone to participate in this research?
"The trial is open to 25 participants that have been diagnosed with sickle cell anemia and are between 18 and 65 years of age. To be eligible for the study, patients must meet any one of four criteria: iii. Chronic transfusion therapy or over 35 years old or male gender; e. 2-year mortality higher than 10-15%; c. Hemoglobin S-Beta-zero Thalassemia; d. Hemoglobin S-Beta plus Thalassemia along with a recent episode of multi organ failure within 5 years from their eligibility assessment date."
Are there any slots left for participants in this research effort?
"According to clinicaltrials.gov, the enrolment period for this medical investigation is still open. It was first advertised on October 19th 2015 and underwent its last update in May 27th 2022."
Are individuals aged thirty or above eligible to participate in the trial?
"This trial is open to patients aged 18 to 65. However, if the patient's age falls outside this range they may be eligible for one of 279 trials aimed at those below 18 or 370 studies meant for people over 65."
Share this study with friends
Copy Link
Messenger